Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
significant i » significant _ (Expand Search), significant co (Expand Search), significant 17 (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
significant i » significant _ (Expand Search), significant co (Expand Search), significant 17 (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
-
141
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
142
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
143
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
144
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
145
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
146
-
147
-
148
-
149
-
150
Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif
Published 2024“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
-
151
Association of <i>Shigella</i> infections with EE biomarker concentration over time.
Published 2025Subjects: -
152
-
153
-
154
FK506 significantly potentiates caspofungin activity against tolerant <i>C. tropicalis</i> strains, reversing tolerance phenotypes in both <i>in vitro</i> and <i>in vivo</i> models...
Published 2025“…(F) FK506 substantially decreases the fungal load in <i>G. mellonella</i> larvae infected with tolerant strains and treated with caspofungin. …”
-
155
-
156
Clinical characteristics.
Published 2025“…FHD was associated with increased risk for neuropathy (HR 1.41 [95%CI 1.11–1.81]) but decreased risk for macrovascular disease (HR 0.84 [95%CI 0.71–0.99]). …”
-
157
Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx
Published 2025“…Compared to the control group, the prehospital TXA group exhibited a significant reduction in 24-h mortality with an OR of 0.72 and a 95% CI of 0.54–0.94 (p = 0.02), while no statistically significant difference in the incidence of venous thromboembolism (VTE; OR: 1.14, 95% CI: 0.98–1.33, p = 0.09). …”
-
158
Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae
Published 2025“…We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …”
-
159
-
160